Table 1.
Baseline characteristic among patients with primary Sjögren’s syndrome and controls.
| Controls n = 16,700 | Sjögren’s syndrome n = 4,175 | p-value | |
|---|---|---|---|
| Age at baseline | 50.12 ± 16.80 | 50.12 ± 16.80 | 1.0000 |
| Sex | 1.0000 | ||
| Female | 12,592(75.40%) | 3,148(75.40%) | |
| Male | 4,108(24.60%) | 1,027(24.60%) | |
| Co-morbidities | |||
| Diabetes mellitus | 1535(9.19%) | 509(12.19%) | <0.0001 |
| Hypertension | 3286(19.68%) | 955(22.87%) | <0.0001 |
| Hyperlipidaemia | 2122(12.71%) | 733(17.56%) | <0.0001 |
| COPD | 1848(11.07%) | 746(17.87%) | <0.0001 |
| Stroke | 480(2.87%) | 179(4.29%) | <0.0001 |
| Chronic kidney disease | 406(2.43%) | 133(3.19%) | 0.0060 |
| Alcohol-Related Disease | 87(0.52%) | 34(0.81%) | 0.0255 |
| Chronic liver diseases | 1118(6.69%) | 540(12.93%) | <0.0001 |
| Cancer | 591(3.54%) | 210(5.03%) | <0.0001 |
| Medications | |||
| Antihyperglycemic drugs | 1040(6.23%) | 287(6.87%) | 0.1256 |
| Antihypertensive drugs | 2852(17.08%) | 952(22.80%) | <0.0001 |
| Statin | 691(4.14%) | 203(4.86%) | 0.0386 |
| Corticosteroids (oral) | 371(2.22%) | 464(11.11%) | <0.0001 |
| NSAID | 1928(11.54%) | 1031(24.69%) | <0.0001 |
| DMARDs* | 9(0.05%) | 657(15.74%) | <0.0001 |
| Aspirin | 541(3.24%) | 203(4.86%) | <0.0001 |
| PPI | 212(1.27%) | 160(3.83%) | <0.0001 |
| H2 Receptor | 485(2.9%) | 262(6.28%) | <0.0001 |
COPD, chronic obstructive pulmonary disease; DMARDs, disease-modifying antirheumatic drugs; NSAID, nonsteroidal antiinflammatory drugs; PPI, proton pump inhibitors.
*DMARDs, including Hydroxychloroquine, Methotrexate, Sulfasalazine.